目的 探討二十五味珊瑚丸聯(lián)合左乙拉西坦片治療癲癇的臨床療效。方法 選取2015年4月至2016年10月中國人民解放軍第二五四醫(yī)院、天津市環(huán)湖醫(yī)院收治的癲癇患者30例為研究對象，按照序列號法將患者隨機分為對照組和治療組，每組各30例。對照組餐后口服左乙拉西坦片，起始劑量500 mg/次，2次/d，一周后加至1 000 mg/次，2次/d。治療組在對照組治療基礎上口服二十五味珊瑚丸，1 g/次，1次/d。兩組患者均連續(xù)治療3個月。觀察兩組的臨床療效，比較兩組的淋巴細胞亞群水平、炎癥因子水平、癲癇發(fā)作頻率。結(jié)果 治療后，對照組和治療組的總有效率分別為73.33%、93.33%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組CD3⁺、CD4⁺、CD4⁺/CD8⁺水平明顯升高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組淋巴細胞亞群水平明顯高于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組可溶性細胞間黏附分子-1（sICAM-1）、白細胞介素-6（IL-6）、C反應蛋白（CRP）水平均明顯降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組炎癥因子水平明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組癲癇發(fā)作頻率明顯降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組癲癇發(fā)作頻率明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 二十五味珊瑚丸聯(lián)合左乙拉西坦片治療癲癇具有較好的臨床療效，可減少癲癇發(fā)作頻率，改善患者免疫功能，減輕炎癥反應，具有一定的臨床推廣應用價值。

Objective To investigate the effect of Ershiwuwei Shanhu Pills combined with Levetiracetam Tablets in treatment of epilepsy. Methods Patients (60 cases) with epilepsy in the No. 254 Hospital of PLA and Tianjin Huanhu Hospital from April 2015 to October 2016 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Levetiracetam Tablets after meal with starting dosage 500 mg/time, twice daily, after 1 week, dose increased to 1 000 mg/time, twice daily. Patients in the treatment group were po administered with Ershiwuwei Shanhu Pills on the basis of the control group, 1 g/time, once daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the frequency of the levels of lymphocyte subgroup, the levels of inflammatory factors, and frequency of epileptic seizures in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.33% and 93.33%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the levels of lymphocyte subgroup in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of sICAM-1, IL-6, and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the frequencies of epileptic seizures in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the frequencies of epileptic seizures in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Ershiwuwei Shanhu Pills combined with Levetiracetam Tablets has clinical curative effect in treatment of epilepsy, can decrease the frequency of epileptic seizures, improve the immune function of patients, and reduce the inflammatory response, which has a certain clinical application value.